Global HER-2 Targeted Drugs for Breast Cancer Market 2019 by Company, Regions, Type and Application, Forecast to 2024

Table of Contents

1 HER-2 Targeted Drugs for Breast Cancer Market Overview

• 1.1 Product Overview and Scope of HER-2 Targeted Drugs for Breast Cancer
• 1.2 Classification of HER-2 Targeted Drugs for Breast Cancer by Types
  • 1.2.1 Global HER-2 Targeted Drugs for Breast Cancer Revenue Comparison by Types (2019-2024)
  • 1.2.2 Global HER-2 Targeted Drugs for Breast Cancer Revenue Market Share by Types in 2018
  • 1.2.3 Trastuzumab
  • 1.2.4 Pertuzumab
  • 1.2.5 Lapatinib
  • 1.2.6 Neratinib
  • 1.2.7 Trastuzumab Emtansine
  • 1.2.8 Pyrotinib
  • 1.2.9 Other
• 1.3 Global HER-2 Targeted Drugs for Breast Cancer Market by Application
  • 1.3.1 Global HER-2 Targeted Drugs for Breast Cancer Market Size and Market Share Comparison by Applications (2014-2024)
  • 1.3.2 Hospital
  • 1.3.3 Clinic
  • 1.3.4 Drug Center
  • 1.3.5 Other
• 1.4 Global HER-2 Targeted Drugs for Breast Cancer Market by Regions
  • 1.4.1 Global HER-2 Targeted Drugs for Breast Cancer Market Size (Million USD) Comparison by Regions (2014-2024)
  • 1.4.1 North America (USA, Canada and Mexico) HER-2 Targeted Drugs for Breast Cancer Status and Prospect (2014-2024)
  • 1.4.2 Europe (Germany, France, UK, Russia and Italy) HER-2 Targeted Drugs for Breast Cancer Status and Prospect (2014-2024)
  • 1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) HER-2 Targeted Drugs for Breast Cancer Status and Prospect (2014-2024)
  • 1.4.4 South America (Brazil, Argentina, Colombia) HER-2 Targeted Drugs for Breast Cancer Status and Prospect (2014-2024)
  • 1.4.5 Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) HER-2 Targeted Drugs for Breast Cancer Status and Prospect (2014-2024)
• 1.5 Global Market Size of HER-2 Targeted Drugs for Breast Cancer (2014-2024)

2 Manufacturers Profiles

• 2.1 Roche
  • 2.1.1 Business Overview
  • 2.1.2 HER-2 Targeted Drugs for Breast Cancer Type and Applications
    • 2.1.2.1 Product A
    • 2.1.2.2 Product B
  • 2.1.3 Roche HER-2 Targeted Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2017-2018)
• 2.2 Chugai Pharmaceutical
  • 2.2.1 Business Overview
  • 2.2.2 HER-2 Targeted Drugs for Breast Cancer Type and Applications
    • 2.2.2.1 Product A
    • 2.2.2.2 Product B
  • 2.2.3 Chugai Pharmaceutical HER-2 Targeted Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2017-2018)
• 2.3 GlaxoSmithKline
  • 2.3.1 Business Overview
  • 2.3.2 HER-2 Targeted Drugs for Breast Cancer Type and Applications
    • 2.3.2.1 Product A
    • 2.3.2.2 Product B
  • 2.3.3 GlaxoSmithKline HER-2 Targeted Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2017-2018)
• 2.4 Novartis
  • 2.4.1 Business Overview
  • 2.4.2 HER-2 Targeted Drugs for Breast Cancer Type and Applications
    • 2.4.2.1 Product A
    • 2.4.2.2 Product B
  • 2.4.3 Novartis HER-2 Targeted Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2017-2018)
• 2.5 Pfizer
  • 2.5.1 Business Overview
  • 2.5.2 HER-2 Targeted Drugs for Breast Cancer Type and Applications
    • 2.5.2.1 Product A
    • 2.5.2.2 Product B
  • 2.5.3 Pfizer HER-2 Targeted Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2017-2018)
• 2.6 CANbridge
  • 2.6.1 Business Overview
  • 2.6.2 HER-2 Targeted Drugs for Breast Cancer Type and Applications
    • 2.6.2.1 Product A
    • 2.6.2.2 Product B
  • 2.6.3 CANbridge HER-2 Targeted Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2017-2018)
• 2.7 Puma Biotechnology
  • 2.7.1 Business Overview
  • 2.7.2 HER-2 Targeted Drugs for Breast Cancer Type and Applications
    • 2.7.2.1 Product A
    • 2.7.2.2 Product B
  • 2.7.3 Puma Biotechnology HER-2 Targeted Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2017-2018)
• 2.8 Hengrui Medicine
  • 2.8.1 Business Overview
  • 2.8.2 HER-2 Targeted Drugs for Breast Cancer Type and Applications
    • 2.8.2.1 Product A
    • 2.8.2.2 Product B
  • 2.8.3 Hengrui Medicine HER-2 Targeted Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2017-2018)
• 2.9 Beacon Pharmaceuticals Limited
  • 2.9.1 Business Overview
  • 2.9.2 HER-2 Targeted Drugs for Breast Cancer Type and Applications
    • 2.9.2.1 Product A
    • 2.9.2.2 Product B
  • 2.9.3 Beacon Pharmaceuticals Limited HER-2 Targeted Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2017-2018)
• 2.10 Hetero Drugs
  • 2.10.1 Business Overview
  • 2.10.2 HER-2 Targeted Drugs for Breast Cancer Type and Applications
    • 2.10.2.1 Product A
    • 2.10.2.2 Product B
  • 2.10.3 Hetero Drugs HER-2 Targeted Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2017-2018)

3 Global HER-2 Targeted Drugs for Breast Cancer Market Competition, by Players

• 3.1 Global HER-2 Targeted Drugs for Breast Cancer Revenue and Share by Players (2014-2019)
• 3.2 Market Concentration Rate
  • 3.2.1 Top 5 HER-2 Targeted Drugs for Breast Cancer Players Market Share
  • 3.2.2 Top 10 HER-2 Targeted Drugs for Breast Cancer Players Market Share
• 3.3 Market Competition Trend

4 Global HER-2 Targeted Drugs for Breast Cancer Market Size by Regions

• 4.1 Global HER-2 Targeted Drugs for Breast Cancer Revenue and Market Share by Regions
• 4.2 North America HER-2 Targeted Drugs for Breast Cancer Revenue and Growth Rate (2014-2019)
• 4.3 Europe HER-2 Targeted Drugs for Breast Cancer Revenue and Growth Rate (2014-2019)
• 4.4 Asia-Pacific HER-2 Targeted Drugs for Breast Cancer Revenue and Growth Rate (2014-2019)
• 4.5 South America HER-2 Targeted Drugs for Breast Cancer Revenue and Growth Rate (2014-2019)
• 4.6 Middle East and Africa HER-2 Targeted Drugs for Breast Cancer Revenue and Growth Rate (2014-2019)

5 North America HER-2 Targeted Drugs for Breast Cancer Revenue by Countries

• 5.1 North America HER-2 Targeted Drugs for Breast Cancer Revenue by Countries (2014-2019)
• 5.2 USA HER-2 Targeted Drugs for Breast Cancer Revenue and Growth Rate (2014-2019)
• 5.3 Canada HER-2 Targeted Drugs for Breast Cancer Revenue and Growth Rate (2014-2019)
• 5.4 Mexico HER-2 Targeted Drugs for Breast Cancer Revenue and Growth Rate (2014-2019)

6 Europe HER-2 Targeted Drugs for Breast Cancer Revenue by Countries

• 6.1 Europe HER-2 Targeted Drugs for Breast Cancer Revenue by Countries (2014-2019)
• 6.2 Germany HER-2 Targeted Drugs for Breast Cancer Revenue and Growth Rate (2014-2019)
• 6.3 UK HER-2 Targeted Drugs for Breast Cancer Revenue and Growth Rate (2014-2019)
• 6.4 France HER-2 Targeted Drugs for Breast Cancer Revenue and Growth Rate (2014-2019)
• 6.5 Russia HER-2 Targeted Drugs for Breast Cancer Revenue and Growth Rate (2014-2019)
• 6.6 Italy HER-2 Targeted Drugs for Breast Cancer Revenue and Growth Rate (2014-2019)

7 Asia-Pacific HER-2 Targeted Drugs for Breast Cancer Revenue by Countries

• 7.1 Asia-Pacific HER-2 Targeted Drugs for Breast Cancer Revenue by Countries (2014-2019)
• 7.2 China HER-2 Targeted Drugs for Breast Cancer Revenue and Growth Rate (2014-2019)
• 7.3 Japan HER-2 Targeted Drugs for Breast Cancer Revenue and Growth Rate (2014-2019)
• 7.4 Korea HER-2 Targeted Drugs for Breast Cancer Revenue and Growth Rate (2014-2019)
• 7.5 India HER-2 Targeted Drugs for Breast Cancer Revenue and Growth Rate (2014-2019)
• 7.6 Southeast Asia HER-2 Targeted Drugs for Breast Cancer Revenue and Growth Rate (2014-2019)

8 South America HER-2 Targeted Drugs for Breast Cancer Revenue by Countries

• 8.1 South America HER-2 Targeted Drugs for Breast Cancer Revenue by Countries (2014-2019)
• 8.2 Brazil HER-2 Targeted Drugs for Breast Cancer Revenue and Growth Rate (2014-2019)
• 8.3 Argentina HER-2 Targeted Drugs for Breast Cancer Revenue and Growth Rate (2014-2019)
• 8.4 Colombia HER-2 Targeted Drugs for Breast Cancer Revenue and Growth Rate (2014-2019)

9 Middle East and Africa Revenue HER-2 Targeted Drugs for Breast Cancer by Countries

• 9.1 Middle East and Africa HER-2 Targeted Drugs for Breast Cancer Revenue by Countries (2014-2019)
• 9.2 Saudi Arabia HER-2 Targeted Drugs for Breast Cancer Revenue and Growth Rate (2014-2019)
• 9.3 UAE HER-2 Targeted Drugs for Breast Cancer Revenue and Growth Rate (2014-2019)
• 9.4 Egypt HER-2 Targeted Drugs for Breast Cancer Revenue and Growth Rate (2014-2019)
• 9.5 Nigeria HER-2 Targeted Drugs for Breast Cancer Revenue and Growth Rate (2014-2019)
• 9.6 South Africa HER-2 Targeted Drugs for Breast Cancer Revenue and Growth Rate (2014-2019)

10 Global HER-2 Targeted Drugs for Breast Cancer Market Segment by Type

• 10.1 Global HER-2 Targeted Drugs for Breast Cancer Revenue and Market Share by Type (2014-2019)
• 10.2 Global HER-2 Targeted Drugs for Breast Cancer Market Forecast by Type (2019-2024)
• 10.3 Trastuzumab Revenue Growth Rate (2014-2024)
• 10.4 Pertuzumab Revenue Growth Rate (2014-2024)
• 10.5 Lapatinib Revenue Growth Rate (2014-2024)
• 10.6 Neratinib Revenue Growth Rate (2014-2024)
• 10.7 Trastuzumab Emtansine Revenue Growth Rate (2014-2024)
• 10.8 Pyrotinib Revenue Growth Rate (2014-2024)
• 10.9 Other Revenue Growth Rate (2014-2024)

11 Global HER-2 Targeted Drugs for Breast Cancer Market Segment by Application

• 11.1 Global HER-2 Targeted Drugs for Breast Cancer Revenue Market Share by Application (2014-2019)
• 11.2 HER-2 Targeted Drugs for Breast Cancer Market Forecast by Application (2019-2024)
• 11.3 Hospital Revenue Growth (2014-2019)
• 11.4 Clinic Revenue Growth (2014-2019)
• 11.5 Drug Center Revenue Growth (2014-2019)
• 11.6 Other Revenue Growth (2014-2019)

12 Global HER-2 Targeted Drugs for Breast Cancer Market Size Forecast (2019-2024)

• 12.1 Global HER-2 Targeted Drugs for Breast Cancer Market Size Forecast (2019-2024)
• 12.2 Global HER-2 Targeted Drugs for Breast Cancer Market Forecast by Regions (2019-2024)
• 12.3 North America HER-2 Targeted Drugs for Breast Cancer Revenue Market Forecast (2019-2024)
• 12.4 Europe HER-2 Targeted Drugs for Breast Cancer Revenue Market Forecast (2019-2024)
• 12.5 Asia-Pacific HER-2 Targeted Drugs for Breast Cancer Revenue Market Forecast (2019-2024)
• 12.6 South America HER-2 Targeted Drugs for Breast Cancer Revenue Market Forecast (2019-2024)
• 12.7 Middle East and Africa HER-2 Targeted Drugs for Breast Cancer Revenue Market Forecast (2019-2024)

13 Research Findings and Conclusion

14 Appendix

• 14.1 Methodology